<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083693</url>
  </required_header>
  <id_info>
    <org_study_id>P10-726</org_study_id>
    <nct_id>NCT01083693</nct_id>
  </id_info>
  <brief_title>Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs</brief_title>
  <official_title>An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Group Data Management Biostatistics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this post-marketing observational study is to obtain further data on the
      evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with
      Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) after
      unsustainable clinical response to disease modifying antirheumatic drugs (DMARD) and or
      biological disease modifying antirheumatic drugs (BDMARD). Treatment strategies in moderate
      to severe rheumatoid arthritis, psoriatic arthritis and in severe active ankylosing
      spondylitis commonly consist of introducing biologics after conventional disease modifying
      antirheumatic drugs or non steroidal antiinflammatory drugs fail. Although biologic disease
      modifying antirheumatic drugs are generally well-tolerated, intolerances may develop or
      efficacy may diminish, at which time another biologic disease modifying antirheumatic drug
      might be considered. This study shall evaluate the quality of life outcomes of HUMIRA®, given
      after conventional disease modifying antirheumatic drugs and or non antiinflammatory drug
      failures and or after biological disease modifying antirheumatic drug failures . Failure in
      this context means primary or secondary loss of efficacy or intolerance to the initial agent.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RA and if Reasonable for PsA Patients Health Assessment Questionnaire Disability Index HAQ-DI</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>The HAQ-DI is a questionnaire that measures functional status (disability) and health-related quality of life. It measures a patient's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene,reach, grip, activities. Each question is evaluated according to the degree of severity on a scale ranging from 0 (without any difficulty) to 3 (unable to do).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 as Generic Measure of Health Status for RA, PsA, AS Physical Score Measures How Decrements in Physical Function Affect Day-to-day Activities Impact of Physical Impairment/Disability on QoL ,Mental Score: Impact of Mental Effect, Symptoms of Pain</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>Medical Outcomes Study Short Form 36 (MOS SF-36) is generic assessment of health status that consists of 36 questions within 8 domains including Physical Functioning (PF), Role Functioning - Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Functioning - Emotional (RE), Mental Health (MH) and Reported Health Transition (HT). Results from each domain are summarized and transformed into a scale ranging from 0 (worst) to 100 (best) with the exception of HT. The score range for HT is 0 (worst) to 5 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EQ-5D for RA,PsA,AS, as Measure of Health Outcome. Self Reported Health Status: Measures Mobility, Self Care, Usual Activities, Pain Discomfort, Anxiety Depression</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>European Quality of Life 5 Dimensions (EQ-5D) is a self-reported health outcome which measures mobility, self care, usual activities, pain discomfort, anxiety depression. An overall score is derived that measures from -0.59 (worst) to +1 (best).
In addition, health state is measured on the thermometer scale (score 0 to 100) with higher scores representing better health status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAS28: Changes in Disease Activity Score 28 in Patients With RA and if Reasonable in PsA: Measures the no. of Swollen and Tender Joints (28 Joints), Erythrocyte Sedimentation Rate, Patients Global Assessment of Disease Activity on a Visual Scale</measure>
    <time_frame>Baseline,months 3,6,9,12</time_frame>
    <description>The Disease Activity Score 28 measures disease activity based on the number of swollen and tender joints (28 joints), erythrocyte sedimentation rate, and patient's global assessment of disease activity on a visual scale. DAS28 is a unit scale from 0 (best value) to 10.0 (worst value).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Bath Ankylosing Spondylitis Disease Activity Index in Patients With AS: Measures Patients Fatigue, Pain (Neck, Hip, Other Joints), Tender Sensitive Body Sites, Morning Stiffness</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>Bath as Disease Activity Index (BASDI) measures fatigue, pain (neck, hip, other joints), tender sensitive body sites, and morning stiffness for patients suffering from AS. Scores range from 0 to 10 with higher scores representing worse disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician´s /Patient's Global Assessment on Disease Activity Measured on a Visual Analogue Scale, for RA and PsA Patients Only</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>Physician's and Patient's Global Assessment of Disease Activity (PGA) are measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician´s / Patient's Global Assessment of State of Health (GH) Measured on a Visual Analogue Scale, for RA and PsA Patients Only</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>Physician's and Patient's Global Assessment of State of Health was measured using a visual analogue scale with scores from 0 to 100 (higher scores indicate worse health state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>Erythrocyte sedimentation rate (ESR) is a nonspecific lab value that measures inflammation from arthritic disease. A decrease in the level indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>Baseline, months 3,6,9,12</time_frame>
    <description>The test for C-Reactive Protein (CRP) is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">162</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis</arm_group_label>
    <description>Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic and medical practice specialized in rheumatology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age greater than or equal to 18

          -  Patients must fulfill international and national guidelines for use of a BDMARD in RA,
             PsA and AS (Chest X-ray and purified protein derivative (PPD) skin test negative for
             tuberculosis).

        In addition one of the following criteria must be fulfilled:

          -  unsatisfactory DMARD response defined as failure to treatment with at least two DMARDs
             including Methotrexate in patients with RA or PsA

          -  unsatisfactory NSAID response in patients with AS or

          -  unsatisfactory response to prior BDMARDs (in this case patients must have received
             BDMARDs at least 12 weeks before visit 1) in patients with RA or PsA or AS.

        Exclusion Criteria:

          -  Patients who meet contraindications as outlined in the latest version of the Humira
             syringe® Summary of Product Characteristics (SmPC) and Humira Pen® SmPC

          -  Patients participating in another study or clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Dworan-Timler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott AUSTRIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32372</name>
      <address>
        <city>Amstetten</city>
        <zip>A-3300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32368</name>
      <address>
        <city>Bludenz</city>
        <zip>A-6700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32367</name>
      <address>
        <city>Gloggnitz</city>
        <zip>A-2640</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 37123</name>
      <address>
        <city>Graz</city>
        <zip>A-8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 37125</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32375</name>
      <address>
        <city>Klagenfurt</city>
        <zip>A-9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32365</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32369</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32371</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32376</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32373</name>
      <address>
        <city>Neudorf</city>
        <zip>A-2351</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32364</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 18782</name>
      <address>
        <city>Vienna</city>
        <zip>A-1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32363</name>
      <address>
        <city>Vienna</city>
        <zip>A-1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32377</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32378</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32366</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32374</name>
      <address>
        <city>Voecklabruck</city>
        <zip>A-4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 32370</name>
      <address>
        <city>Weiz</city>
        <zip>A-8160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Ref # / Investigator 37124</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>June 28, 2011</results_first_submitted>
  <results_first_submitted_qc>June 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2011</results_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Astrid Dworan-Timler, Medical Director</name_title>
    <organization>Abbott AUSTRIA</organization>
  </responsible_party>
  <keyword>Monoclonals</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <keyword>Antirheumatic Agents</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>psoriatic arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 162 participants were screened for this study. Of those, 161 are included in the analysis as one participant was a screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis (RA)</title>
          <description>Rheumatoid Arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="P2">
          <title>Psoriasis Arthritis (PsA)</title>
          <description>Psoriatic Arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="P3">
          <title>Ankylosing Spondylitis (AS)</title>
          <description>Ankylosing Spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of effectiveness</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Complete remission</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other medical condition/surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason unknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis (RA)</title>
          <description>Rheumatoid Arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="B2">
          <title>Psoriasis Arthritis (PsA)</title>
          <description>Psoriatic Arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="B3">
          <title>Ankylosing Spondylitis (AS)</title>
          <description>Ankylosing Spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="14.2"/>
                    <measurement group_id="B2" value="47.9" spread="8.1"/>
                    <measurement group_id="B3" value="42.0" spread="12.9"/>
                    <measurement group_id="B4" value="50.9" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of underlying disease</title>
          <description>Average duration (years) of underlying disease</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="7.4"/>
                    <measurement group_id="B2" value="6.2" spread="6.8"/>
                    <measurement group_id="B3" value="8.9" spread="11.4"/>
                    <measurement group_id="B4" value="7.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>RA and if Reasonable for PsA Patients Health Assessment Questionnaire Disability Index HAQ-DI</title>
        <description>The HAQ-DI is a questionnaire that measures functional status (disability) and health-related quality of life. It measures a patient's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene,reach, grip, activities. Each question is evaluated according to the degree of severity on a scale ranging from 0 (without any difficulty) to 3 (unable to do).</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N =121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>RA and if Reasonable for PsA Patients Health Assessment Questionnaire Disability Index HAQ-DI</title>
          <description>The HAQ-DI is a questionnaire that measures functional status (disability) and health-related quality of life. It measures a patient's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene,reach, grip, activities. Each question is evaluated according to the degree of severity on a scale ranging from 0 (without any difficulty) to 3 (unable to do).</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N =121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="0.9" spread="0.7"/>
                    <measurement group_id="O3" value="1.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.7"/>
                    <measurement group_id="O2" value="0.4" spread="0.4"/>
                    <measurement group_id="O3" value="0.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.6"/>
                    <measurement group_id="O2" value="0.4" spread="0.5"/>
                    <measurement group_id="O3" value="0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.6"/>
                    <measurement group_id="O2" value="0.3" spread="0.5"/>
                    <measurement group_id="O3" value="0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.6"/>
                    <measurement group_id="O2" value="0.2" spread="0.3"/>
                    <measurement group_id="O3" value="0.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.9"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SF-36 as Generic Measure of Health Status for RA, PsA, AS Physical Score Measures How Decrements in Physical Function Affect Day-to-day Activities Impact of Physical Impairment/Disability on QoL ,Mental Score: Impact of Mental Effect, Symptoms of Pain</title>
        <description>Medical Outcomes Study Short Form 36 (MOS SF-36) is generic assessment of health status that consists of 36 questions within 8 domains including Physical Functioning (PF), Role Functioning - Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Functioning - Emotional (RE), Mental Health (MH) and Reported Health Transition (HT). Results from each domain are summarized and transformed into a scale ranging from 0 (worst) to 100 (best) with the exception of HT. The score range for HT is 0 (worst) to 5 (best).</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N=161) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [participants who discontinued the study early]) in each disease group. No participants in the PsA or the AS group attended an early termination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis (AS)</title>
            <description>Ankylosing spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36 as Generic Measure of Health Status for RA, PsA, AS Physical Score Measures How Decrements in Physical Function Affect Day-to-day Activities Impact of Physical Impairment/Disability on QoL ,Mental Score: Impact of Mental Effect, Symptoms of Pain</title>
          <description>Medical Outcomes Study Short Form 36 (MOS SF-36) is generic assessment of health status that consists of 36 questions within 8 domains including Physical Functioning (PF), Role Functioning - Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Functioning - Emotional (RE), Mental Health (MH) and Reported Health Transition (HT). Results from each domain are summarized and transformed into a scale ranging from 0 (worst) to 100 (best) with the exception of HT. The score range for HT is 0 (worst) to 5 (best).</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N=161) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [participants who discontinued the study early]) in each disease group. No participants in the PsA or the AS group attended an early termination visit.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning -Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="26.4"/>
                    <measurement group_id="O2" value="58.1" spread="26.2"/>
                    <measurement group_id="O3" value="53.3" spread="23.4"/>
                    <measurement group_id="O4" value="53.1" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="24.3"/>
                    <measurement group_id="O2" value="74.3" spread="21.3"/>
                    <measurement group_id="O3" value="76.5" spread="21.9"/>
                    <measurement group_id="O4" value="71.0" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="24.4"/>
                    <measurement group_id="O2" value="76.0" spread="21.9"/>
                    <measurement group_id="O3" value="79.4" spread="22.2"/>
                    <measurement group_id="O4" value="70.9" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="24.6"/>
                    <measurement group_id="O2" value="79.8" spread="19.5"/>
                    <measurement group_id="O3" value="81.4" spread="18.7"/>
                    <measurement group_id="O4" value="73.4" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning -12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" spread="23.8"/>
                    <measurement group_id="O2" value="85.9" spread="13.2"/>
                    <measurement group_id="O3" value="80.4" spread="24.5"/>
                    <measurement group_id="O4" value="75.9" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="28.6"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="33.3" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning -Physical - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="40.5"/>
                    <measurement group_id="O2" value="38.9" spread="43.5"/>
                    <measurement group_id="O3" value="25.0" spread="32.2"/>
                    <measurement group_id="O4" value="30.3" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Physical - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="43.5"/>
                    <measurement group_id="O2" value="58.7" spread="41.0"/>
                    <measurement group_id="O3" value="67.4" spread="38.8"/>
                    <measurement group_id="O4" value="60.2" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Physical - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="44.0"/>
                    <measurement group_id="O2" value="70.2" spread="36.8"/>
                    <measurement group_id="O3" value="73.4" spread="37.6"/>
                    <measurement group_id="O4" value="62.7" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Physical - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="43.7"/>
                    <measurement group_id="O2" value="72.5" spread="40.5"/>
                    <measurement group_id="O3" value="75.0" spread="37.2"/>
                    <measurement group_id="O4" value="63.8" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Physical - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="42.3"/>
                    <measurement group_id="O2" value="85.0" spread="28.6"/>
                    <measurement group_id="O3" value="75.9" spread="38.9"/>
                    <measurement group_id="O4" value="68.9" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Physical - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="40.1"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="29.2" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="19.2"/>
                    <measurement group_id="O2" value="36.6" spread="23.9"/>
                    <measurement group_id="O3" value="27.7" spread="19.1"/>
                    <measurement group_id="O4" value="32.7" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain- 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" spread="24.3"/>
                    <measurement group_id="O2" value="61.0" spread="23.5"/>
                    <measurement group_id="O3" value="66.1" spread="24.9"/>
                    <measurement group_id="O4" value="59.8" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain- 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" spread="19.9"/>
                    <measurement group_id="O2" value="64.9" spread="23.7"/>
                    <measurement group_id="O3" value="67.7" spread="25.2"/>
                    <measurement group_id="O4" value="59.5" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain- 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="21.6"/>
                    <measurement group_id="O2" value="69.3" spread="25.9"/>
                    <measurement group_id="O3" value="69.8" spread="22.5"/>
                    <measurement group_id="O4" value="64.0" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain- 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="19.1"/>
                    <measurement group_id="O2" value="74.0" spread="23.2"/>
                    <measurement group_id="O3" value="71.2" spread="27.9"/>
                    <measurement group_id="O4" value="67.0" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain- Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="37.6"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="25.7" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="19.4"/>
                    <measurement group_id="O2" value="41.9" spread="18.9"/>
                    <measurement group_id="O3" value="39.1" spread="16.4"/>
                    <measurement group_id="O4" value="41.8" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="17.9"/>
                    <measurement group_id="O2" value="53.0" spread="20.8"/>
                    <measurement group_id="O3" value="59.0" spread="21.7"/>
                    <measurement group_id="O4" value="53.8" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" spread="16.6"/>
                    <measurement group_id="O2" value="61.6" spread="18.0"/>
                    <measurement group_id="O3" value="60.1" spread="23.7"/>
                    <measurement group_id="O4" value="57.0" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" spread="19.0"/>
                    <measurement group_id="O2" value="59.8" spread="19.1"/>
                    <measurement group_id="O3" value="65.7" spread="22.1"/>
                    <measurement group_id="O4" value="58.7" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="20.2"/>
                    <measurement group_id="O2" value="65.0" spread="18.1"/>
                    <measurement group_id="O3" value="66.3" spread="23.0"/>
                    <measurement group_id="O4" value="62.3" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="26.2"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="39.0" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="19.0"/>
                    <measurement group_id="O2" value="39.8" spread="21.1"/>
                    <measurement group_id="O3" value="32.4" spread="18.7"/>
                    <measurement group_id="O4" value="37.7" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="19.3"/>
                    <measurement group_id="O2" value="53.3" spread="19.7"/>
                    <measurement group_id="O3" value="54.5" spread="20.4"/>
                    <measurement group_id="O4" value="53.8" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="16.0"/>
                    <measurement group_id="O2" value="56.8" spread="19.4"/>
                    <measurement group_id="O3" value="57.9" spread="19.4"/>
                    <measurement group_id="O4" value="54.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="19.1"/>
                    <measurement group_id="O2" value="56.3" spread="16.0"/>
                    <measurement group_id="O3" value="59.2" spread="20.1"/>
                    <measurement group_id="O4" value="54.9" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="17.7"/>
                    <measurement group_id="O2" value="65.0" spread="14.9"/>
                    <measurement group_id="O3" value="58.0" spread="21.5"/>
                    <measurement group_id="O4" value="58.7" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="16.3"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="23.3" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="30.0"/>
                    <measurement group_id="O2" value="66.2" spread="31.2"/>
                    <measurement group_id="O3" value="52.8" spread="25.0"/>
                    <measurement group_id="O4" value="59.1" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="20.9"/>
                    <measurement group_id="O2" value="79.3" spread="18.7"/>
                    <measurement group_id="O3" value="78.0" spread="21.4"/>
                    <measurement group_id="O4" value="76.8" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="20.5"/>
                    <measurement group_id="O2" value="85.7" spread="19.1"/>
                    <measurement group_id="O3" value="81.0" spread="23.0"/>
                    <measurement group_id="O4" value="80.4" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="19.7"/>
                    <measurement group_id="O2" value="86.9" spread="20.1"/>
                    <measurement group_id="O3" value="83.2" spread="23.2"/>
                    <measurement group_id="O4" value="81.5" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" spread="20.4"/>
                    <measurement group_id="O2" value="93.1" spread="14.3"/>
                    <measurement group_id="O3" value="80.4" spread="25.1"/>
                    <measurement group_id="O4" value="83.8" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="31.0"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="47.9" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning -Emotional - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="44.7"/>
                    <measurement group_id="O2" value="55.6" spread="43.4"/>
                    <measurement group_id="O3" value="40.7" spread="42.2"/>
                    <measurement group_id="O4" value="46.0" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning -Emotional - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" spread="42.3"/>
                    <measurement group_id="O2" value="75.4" spread="41.7"/>
                    <measurement group_id="O3" value="74.0" spread="35.7"/>
                    <measurement group_id="O4" value="69.8" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning -Emotional - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="41.2"/>
                    <measurement group_id="O2" value="82.5" spread="35.9"/>
                    <measurement group_id="O3" value="76.3" spread="36.7"/>
                    <measurement group_id="O4" value="73.7" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning -Emotional - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="40.5"/>
                    <measurement group_id="O2" value="78.3" spread="39.4"/>
                    <measurement group_id="O3" value="81.6" spread="31.6"/>
                    <measurement group_id="O4" value="76.0" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning -Emotional - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="37.0"/>
                    <measurement group_id="O2" value="91.7" spread="26.2"/>
                    <measurement group_id="O3" value="75.0" spread="38.1"/>
                    <measurement group_id="O4" value="79.9" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning - Emotional - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="51.6"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="33.3" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="21.5"/>
                    <measurement group_id="O2" value="63.1" spread="22.1"/>
                    <measurement group_id="O3" value="53.9" spread="21.0"/>
                    <measurement group_id="O4" value="56.6" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="18.8"/>
                    <measurement group_id="O2" value="70.1" spread="19.0"/>
                    <measurement group_id="O3" value="70.4" spread="18.9"/>
                    <measurement group_id="O4" value="67.9" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="16.3"/>
                    <measurement group_id="O2" value="75.8" spread="16.6"/>
                    <measurement group_id="O3" value="73.6" spread="18.9"/>
                    <measurement group_id="O4" value="70.8" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="17.5"/>
                    <measurement group_id="O2" value="74.6" spread="21.1"/>
                    <measurement group_id="O3" value="76.1" spread="18.8"/>
                    <measurement group_id="O4" value="72.9" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="14.8"/>
                    <measurement group_id="O2" value="81.8" spread="13.9"/>
                    <measurement group_id="O3" value="76.7" spread="17.2"/>
                    <measurement group_id="O4" value="75.8" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="23.8"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="41.3" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Health Transition - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.2"/>
                    <measurement group_id="O2" value="3.5" spread="1.1"/>
                    <measurement group_id="O3" value="3.9" spread="1.1"/>
                    <measurement group_id="O4" value="3.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Health Transition - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="2.1" spread="1.1"/>
                    <measurement group_id="O3" value="1.8" spread="1.1"/>
                    <measurement group_id="O4" value="2.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Health Transition - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.0"/>
                    <measurement group_id="O2" value="1.8" spread="1.0"/>
                    <measurement group_id="O3" value="1.5" spread="0.8"/>
                    <measurement group_id="O4" value="1.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Health Transition - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.8"/>
                    <measurement group_id="O2" value="1.8" spread="1.0"/>
                    <measurement group_id="O3" value="1.4" spread="0.6"/>
                    <measurement group_id="O4" value="1.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Health Transition - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.9"/>
                    <measurement group_id="O2" value="1.4" spread="0.6"/>
                    <measurement group_id="O3" value="1.7" spread="0.9"/>
                    <measurement group_id="O4" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported Health Transition - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.0"/>
                    <measurement group_id="O2" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O3" value="NA">Score not available as there were no participants who had an early termination visit in this group.</measurement>
                    <measurement group_id="O4" value="3.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EQ-5D for RA,PsA,AS, as Measure of Health Outcome. Self Reported Health Status: Measures Mobility, Self Care, Usual Activities, Pain Discomfort, Anxiety Depression</title>
        <description>European Quality of Life 5 Dimensions (EQ-5D) is a self-reported health outcome which measures mobility, self care, usual activities, pain discomfort, anxiety depression. An overall score is derived that measures from -0.59 (worst) to +1 (best).
In addition, health state is measured on the thermometer scale (score 0 to 100) with higher scores representing better health status.</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N=161) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis (AS)</title>
            <description>Ankylosing spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D for RA,PsA,AS, as Measure of Health Outcome. Self Reported Health Status: Measures Mobility, Self Care, Usual Activities, Pain Discomfort, Anxiety Depression</title>
          <description>European Quality of Life 5 Dimensions (EQ-5D) is a self-reported health outcome which measures mobility, self care, usual activities, pain discomfort, anxiety depression. An overall score is derived that measures from -0.59 (worst) to +1 (best).
In addition, health state is measured on the thermometer scale (score 0 to 100) with higher scores representing better health status.</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N=161) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.3"/>
                    <measurement group_id="O2" value="0.5" spread="0.3"/>
                    <measurement group_id="O3" value="0.4" spread="0.3"/>
                    <measurement group_id="O4" value="0.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.2"/>
                    <measurement group_id="O4" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.1"/>
                    <measurement group_id="O3" value="0.8" spread="0.3"/>
                    <measurement group_id="O4" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                    <measurement group_id="O3" value="0.8" spread="0.2"/>
                    <measurement group_id="O4" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.1"/>
                    <measurement group_id="O3" value="0.8" spread="0.3"/>
                    <measurement group_id="O4" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="1.0">Only one patient completed this assessment at an early termination visit therefore a standard deviation value is not available.</measurement>
                    <measurement group_id="O3" value="NA">There were no patients who completed this assessment at an early termination visit in this group/arm.</measurement>
                    <measurement group_id="O4" value="0.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thermometer Scale - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" spread="21.5"/>
                    <measurement group_id="O2" value="52.5" spread="24.8"/>
                    <measurement group_id="O3" value="40.2" spread="22.6"/>
                    <measurement group_id="O4" value="47.4" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thermometer Scale - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" spread="22.0"/>
                    <measurement group_id="O2" value="68.7" spread="21.0"/>
                    <measurement group_id="O3" value="64.9" spread="25.6"/>
                    <measurement group_id="O4" value="65.5" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thermometer Scale - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="22.0"/>
                    <measurement group_id="O2" value="68.9" spread="23.3"/>
                    <measurement group_id="O3" value="68.7" spread="29.0"/>
                    <measurement group_id="O4" value="63.7" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thermometer Scale - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="21.0"/>
                    <measurement group_id="O2" value="67.8" spread="25.2"/>
                    <measurement group_id="O3" value="69.2" spread="25.0"/>
                    <measurement group_id="O4" value="68.0" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thermometer Scale - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="18.5"/>
                    <measurement group_id="O2" value="79.2" spread="16.0"/>
                    <measurement group_id="O3" value="71.5" spread="28.5"/>
                    <measurement group_id="O4" value="73.9" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thermometer Scale - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="29.1"/>
                    <measurement group_id="O2" value="100.0">Only one patient completed this assessment at an early termination visit therefore a standard deviation value is not available.</measurement>
                    <measurement group_id="O3" value="NA">There were no patients who completed this assessment at an early termination visit in this group/arm.</measurement>
                    <measurement group_id="O4" value="71.9" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28: Changes in Disease Activity Score 28 in Patients With RA and if Reasonable in PsA: Measures the no. of Swollen and Tender Joints (28 Joints), Erythrocyte Sedimentation Rate, Patients Global Assessment of Disease Activity on a Visual Scale</title>
        <description>The Disease Activity Score 28 measures disease activity based on the number of swollen and tender joints (28 joints), erythrocyte sedimentation rate, and patient's global assessment of disease activity on a visual scale. DAS28 is a unit scale from 0 (best value) to 10.0 (worst value).</description>
        <time_frame>Baseline,months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N=121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>DAS28: Changes in Disease Activity Score 28 in Patients With RA and if Reasonable in PsA: Measures the no. of Swollen and Tender Joints (28 Joints), Erythrocyte Sedimentation Rate, Patients Global Assessment of Disease Activity on a Visual Scale</title>
          <description>The Disease Activity Score 28 measures disease activity based on the number of swollen and tender joints (28 joints), erythrocyte sedimentation rate, and patient's global assessment of disease activity on a visual scale. DAS28 is a unit scale from 0 (best value) to 10.0 (worst value).</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N=121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.2"/>
                    <measurement group_id="O2" value="4.9" spread="1.1"/>
                    <measurement group_id="O3" value="5.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.5"/>
                    <measurement group_id="O2" value="3.0" spread="1.1"/>
                    <measurement group_id="O3" value="3.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.2"/>
                    <measurement group_id="O2" value="2.4" spread="1.0"/>
                    <measurement group_id="O3" value="3.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.5"/>
                    <measurement group_id="O2" value="2.5" spread="1.0"/>
                    <measurement group_id="O3" value="3.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.3"/>
                    <measurement group_id="O2" value="2.5" spread="1.0"/>
                    <measurement group_id="O3" value="3.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.8"/>
                    <measurement group_id="O2" value="2.1" spread="0.8"/>
                    <measurement group_id="O3" value="4.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bath Ankylosing Spondylitis Disease Activity Index in Patients With AS: Measures Patients Fatigue, Pain (Neck, Hip, Other Joints), Tender Sensitive Body Sites, Morning Stiffness</title>
        <description>Bath as Disease Activity Index (BASDI) measures fatigue, pain (neck, hip, other joints), tender sensitive body sites, and morning stiffness for patients suffering from AS. Scores range from 0 to 10 with higher scores representing worse disease activity.</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N=40) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]).</population>
        <group_list>
          <group group_id="O1">
            <title>Ankylosing Spondylitis (AS)</title>
            <description>Ankylosing spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bath Ankylosing Spondylitis Disease Activity Index in Patients With AS: Measures Patients Fatigue, Pain (Neck, Hip, Other Joints), Tender Sensitive Body Sites, Morning Stiffness</title>
          <description>Bath as Disease Activity Index (BASDI) measures fatigue, pain (neck, hip, other joints), tender sensitive body sites, and morning stiffness for patients suffering from AS. Scores range from 0 to 10 with higher scores representing worse disease activity.</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N=40) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician´s /Patient's Global Assessment on Disease Activity Measured on a Visual Analogue Scale, for RA and PsA Patients Only</title>
        <description>Physician's and Patient's Global Assessment of Disease Activity (PGA) are measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity).</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N=121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Physician´s /Patient's Global Assessment on Disease Activity Measured on a Visual Analogue Scale, for RA and PsA Patients Only</title>
          <description>Physician's and Patient's Global Assessment of Disease Activity (PGA) are measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity).</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N=121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician's PGA - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" spread="19.6"/>
                    <measurement group_id="O2" value="52.0" spread="26.9"/>
                    <measurement group_id="O3" value="54.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's PGA - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="21.1"/>
                    <measurement group_id="O2" value="29.0" spread="20.1"/>
                    <measurement group_id="O3" value="28.9" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's PGA - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="20.2"/>
                    <measurement group_id="O2" value="23.1" spread="19.7"/>
                    <measurement group_id="O3" value="28.1" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's PGA - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="19.5"/>
                    <measurement group_id="O2" value="17.9" spread="13.1"/>
                    <measurement group_id="O3" value="26.1" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's PGA - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="16.8"/>
                    <measurement group_id="O2" value="19.4" spread="14.7"/>
                    <measurement group_id="O3" value="22.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's PGA - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="30.5"/>
                    <measurement group_id="O2" value="11.7" spread="12.6"/>
                    <measurement group_id="O3" value="47.3" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's PGA - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="23.3"/>
                    <measurement group_id="O2" value="58.3" spread="27.6"/>
                    <measurement group_id="O3" value="59.6" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's PGA - 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="22.9"/>
                    <measurement group_id="O2" value="34.3" spread="22.3"/>
                    <measurement group_id="O3" value="32.8" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's PGA - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="21.1"/>
                    <measurement group_id="O2" value="27.7" spread="21.9"/>
                    <measurement group_id="O3" value="31.1" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's PGA - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="21.1"/>
                    <measurement group_id="O2" value="22.0" spread="16.9"/>
                    <measurement group_id="O3" value="29.9" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's PGA - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="18.4"/>
                    <measurement group_id="O2" value="23.9" spread="15.9"/>
                    <measurement group_id="O3" value="25.6" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's PGA - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="29.5"/>
                    <measurement group_id="O2" value="21.7" spread="29.3"/>
                    <measurement group_id="O3" value="54.9" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician´s / Patient's Global Assessment of State of Health (GH) Measured on a Visual Analogue Scale, for RA and PsA Patients Only</title>
        <description>Physician's and Patient's Global Assessment of State of Health was measured using a visual analogue scale with scores from 0 to 100 (higher scores indicate worse health state).</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) score is based on the number of participants included in the analysis (N =121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Physician´s / Patient's Global Assessment of State of Health (GH) Measured on a Visual Analogue Scale, for RA and PsA Patients Only</title>
          <description>Physician's and Patient's Global Assessment of State of Health was measured using a visual analogue scale with scores from 0 to 100 (higher scores indicate worse health state).</description>
          <population>Mean (average) score is based on the number of participants included in the analysis (N =121) who completed the assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician's GH - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="21.0"/>
                    <measurement group_id="O2" value="46.8" spread="23.7"/>
                    <measurement group_id="O3" value="50.4" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's GH -3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="22.3"/>
                    <measurement group_id="O2" value="25.3" spread="19.3"/>
                    <measurement group_id="O3" value="28.9" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's GH - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="21.4"/>
                    <measurement group_id="O2" value="26.2" spread="23.9"/>
                    <measurement group_id="O3" value="30.4" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's GH - 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="22.4"/>
                    <measurement group_id="O2" value="26.5" spread="24.5"/>
                    <measurement group_id="O3" value="30.2" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's GH - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="24.1"/>
                    <measurement group_id="O2" value="26.2" spread="26.7"/>
                    <measurement group_id="O3" value="28.3" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's GH - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="28.6"/>
                    <measurement group_id="O2" value="11.7" spread="12.6"/>
                    <measurement group_id="O3" value="46.6" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's GH - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="25.4"/>
                    <measurement group_id="O2" value="59.0" spread="24.8"/>
                    <measurement group_id="O3" value="56.1" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's GH -3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="23.2"/>
                    <measurement group_id="O2" value="31.4" spread="23.4"/>
                    <measurement group_id="O3" value="33.1" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's GH - 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="22.3"/>
                    <measurement group_id="O2" value="29.4" spread="26.6"/>
                    <measurement group_id="O3" value="32.1" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's GH -9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="22.7"/>
                    <measurement group_id="O2" value="26.9" spread="23.4"/>
                    <measurement group_id="O3" value="33.2" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's GH -12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="23.7"/>
                    <measurement group_id="O2" value="30.6" spread="25.7"/>
                    <measurement group_id="O3" value="30.4" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's GH - Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="32.1"/>
                    <measurement group_id="O2" value="21.7" spread="29.3"/>
                    <measurement group_id="O3" value="53.8" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Sedimentation Rate</title>
        <description>Erythrocyte sedimentation rate (ESR) is a nonspecific lab value that measures inflammation from arthritic disease. A decrease in the level indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) value is based on the number of participants included in the analysis (N=161) who completed the lab assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis (AS)</title>
            <description>Ankylosing spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate</title>
          <description>Erythrocyte sedimentation rate (ESR) is a nonspecific lab value that measures inflammation from arthritic disease. A decrease in the level indicates reduction in inflammation and therefore improvement.</description>
          <population>Mean (average) value is based on the number of participants included in the analysis (N=161) who completed the lab assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="22.9"/>
                    <measurement group_id="O2" value="31.7" spread="19.9"/>
                    <measurement group_id="O3" value="25.2" spread="15.7"/>
                    <measurement group_id="O4" value="32.4" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="20.8"/>
                    <measurement group_id="O2" value="16.0" spread="13.9"/>
                    <measurement group_id="O3" value="12.4" spread="12.3"/>
                    <measurement group_id="O4" value="20.6" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="21.9"/>
                    <measurement group_id="O2" value="12.3" spread="13.6"/>
                    <measurement group_id="O3" value="11.9" spread="10.2"/>
                    <measurement group_id="O4" value="19.0" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="22.8"/>
                    <measurement group_id="O2" value="11.6" spread="10.2"/>
                    <measurement group_id="O3" value="11.9" spread="8.4"/>
                    <measurement group_id="O4" value="19.1" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="13.4"/>
                    <measurement group_id="O2" value="10.5" spread="7.7"/>
                    <measurement group_id="O3" value="14.0" spread="12.8"/>
                    <measurement group_id="O4" value="15.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="29.1"/>
                    <measurement group_id="O2" value="18.0" spread="26.5"/>
                    <measurement group_id="O3" value="10.5" spread="2.1"/>
                    <measurement group_id="O4" value="37.3" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Reactive Protein</title>
        <description>The test for C-Reactive Protein (CRP) is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Baseline, months 3,6,9,12</time_frame>
        <population>Mean (average) value is based on the number of participants included in the analysis (N =161) who completed the lab assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA)</title>
            <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O2">
            <title>Psoriasis Arthritis (PsA)</title>
            <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O3">
            <title>Ankylosing Spondylitis (AS)</title>
            <description>Ankylosing spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein</title>
          <description>The test for C-Reactive Protein (CRP) is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>Mean (average) value is based on the number of participants included in the analysis (N =161) who completed the lab assessment at each timepoint (Baseline, 3, 6, 9 and 12 months and early termination [for participants who discontinued the study early]) in each disease group.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.5"/>
                    <measurement group_id="O2" value="1.1" spread="1.0"/>
                    <measurement group_id="O3" value="1.4" spread="1.4"/>
                    <measurement group_id="O4" value="1.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.5"/>
                    <measurement group_id="O2" value="0.7" spread="1.4"/>
                    <measurement group_id="O3" value="0.5" spread="0.6"/>
                    <measurement group_id="O4" value="0.9" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.2"/>
                    <measurement group_id="O2" value="0.4" spread="1.0"/>
                    <measurement group_id="O3" value="0.4" spread="0.6"/>
                    <measurement group_id="O4" value="0.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.6"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.4" spread="0.3"/>
                    <measurement group_id="O4" value="0.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.4"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.7" spread="1.6"/>
                    <measurement group_id="O4" value="0.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="4.7"/>
                    <measurement group_id="O2" value="1.1" spread="2.1"/>
                    <measurement group_id="O3" value="0.4" spread="0.3"/>
                    <measurement group_id="O4" value="2.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and serious adverse events were collected throughout the study (12 months) and 70 days following the last dose of adalimumab.</time_frame>
      <desc>A total of 15 out of 161 participants had at least one adverse event. Percentages for individual adverse events are calculated for each disease group (based on the number of participants in each group) as well as the total number of participants overall.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis (RA)</title>
          <description>Rheumatoid arthritis participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="E2">
          <title>Psoriasis Arthritis (PsA)</title>
          <description>Psoriatic arthritic participants with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="E3">
          <title>Ankylosing Spondylitis (AS)</title>
          <description>Ankylosing spondylitis participants with unsustainable clinical response to nonsteroidal antiinflammatory drugs and or biological disease modifying antirheumatic drugs.</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Uriticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Synovectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

